Relmada Therapeutics (RLMD) shares continued falling on Thursday after some analysts downgraded its stock following failure in late-stage trial of anti-depressant candidate.
Mizuho downgraded the stock to neutral from outperform and slashed its price target to $1 from $23, while Leerink Partners lowered its rating to market perform from outperform, also with a $1 price target.
Relmada on Wednesday said that an independent data monitoring committee has determined that a late-stage study of REL-1017 as an adjunctive treatment for major depressive disorder is "futile." The company will determine its next steps after assessing the full dataset.
The company's stock was down nearly 16% in recent trading after falling more than 70% on Wednesday.
Price: 0.53, Change: -0.10, Percent Change: -15.71
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.